Table 5.
Odds ratio (OR) and 95% confidence interval (CI) of the clinical status and MALAT1 rs1194338 genotypic frequencies in 156 hepatocellular carcinoma patients among smokers.
| Variable | Genotypic Frequencies | |||
|---|---|---|---|---|
| CC (%) (n = 64) |
CA + AA (%) (n = 92) |
OR (95% CI) | p Value | |
| Clinical stage | ||||
| Stage III/IV | 23 (35.9%) | 26 (28.3%) | 0.702 (0.355–1.39) | 0.311 |
| Tumor size | ||||
| >T2 | 23 (35.9%) | 26 (28.3%) | 0.702 (0.355–1.39) | 0.311 |
| Lymph node metastasis | ||||
| Yes | 2 (3.1%) | 3 (3.3%) | 1.045 (0.170–6.439) | 0.962 |
| Distant metastasis | ||||
| Yes | 2 (3.1%) | 5 (5.4%) | 1.782 (0.335–9.482) | 0.498 |
| Vascular invasion | ||||
| Yes | 14 (21.9%) | 11 (12%) | 0.485 (0.204–1.152) | 0.101 |
| Child–Pugh grade | ||||
| B or C | 17 (26.6%) | 12 (13%) | 0.415 (0.182–0.944) | 0.036 * |
| HBsAg | ||||
| Positive | 28 (43.8%) | 38 (41.3%) | 0.905 (0.475–1.725) | 0.761 |
| Anti-HCV | ||||
| Positive | 31 (48.4%) | 40 (43.5%) | 0.819 (0.432–1.554) | 0.541 |
| Liver cirrhosis | ||||
| Positive | 53 (82.8%) | 77 (83.7%) | 1.065 (0.454–2.500) | 0.884 |
The ORs with their 95% CIs were estimated by logistic regression models. >T2: multiple tumors of >5 cm or tumors involving a major branch of the portal or hepatic vein(s). * p value < 0.05 as statistically significant. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.